Open access · CC-BY
via OpenAlex
SENOLYTICS AND SENOMORPHICS: A NEW CLASS OF DRUGS FOR ANTI-AGING THERAPY
Timur M. Saliev, Prim B. Singh
Central Asian Journal of Medical Hypotheses and Ethics · 2025 · ▲ 1 citations
Deregulated nutrient-sensing
Cellular senescence
Chronic inflammation
Senolytics
Rapamycin / mTOR inhibition
Human
Preclinical / animal
Review
Abstract
Aging is a complex biological process characterized by the accumulation of senescent cells that adopt a senescence(definition)-associated secretory phenotype (SASP), releasing proinflammatory mediators that drive tissue dysfunction and the onset of age-related diseases. Targeting cellular senescence has emerged as a novel therapeutic paradigm in geroscience. This review synthesizes recent preclinical and early clinical evidence on two innovative anti-aging strategies, senolytics(definition) and senomorphics, drawing from studies published in the last decade. The analysis focuses on mechanisms of action, therapeutic efficacy, limitations, and translational potential. Senolytics, including dasatinib–quercetin (D+Q) 263), natural compounds such as fisetin, selectively eliminate senescent cells by disrupting anti-apoptotic pathways. Senomorphics, such as mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR inhibition) and ruxolitinib (JAK inhibition), suppress detrimental SASP components while preserving beneficial senescence functions. Both approaches demonstrate promise in extending healthspan(definition) and alleviating age-associated pathologies including fibrosis, neurodegeneration, and metabolic disorders. However, challenges persist, including limited specificity, off-target effects, and the absence of standardized biomarkers for patient selection and treatment monitoring. Senolytic and senomorphic therapies represent a rapidly advancing frontier in anti-aging research with substantial potential to improve healthy lifespan. Future progress will require the integration of combination strategies, precision medicine approaches informed by biomarkers, and advanced drug delivery technologies to enhance efficacy and safety.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.47316/cajmhe.2025.6.3.01
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Saliev, T.M., & Singh, P.B. (2025). SENOLYTICS AND SENOMORPHICS: A NEW CLASS OF DRUGS FOR ANTI-AGING THERAPY. <em>Central Asian Journal of Medical Hypotheses and Ethics</em>. https://doi.org/10.47316/cajmhe.2025.6.3.01
Vancouver
Saliev TM, Singh PB. SENOLYTICS AND SENOMORPHICS: A NEW CLASS OF DRUGS FOR ANTI-AGING THERAPY. Central Asian Journal of Medical Hypotheses and Ethics. 2025. doi:10.47316/cajmhe.2025.6.3.01.
BibTeX
@article{timur2025SENOLY,
title = {SENOLYTICS AND SENOMORPHICS: A NEW CLASS OF DRUGS FOR ANTI-AGING THERAPY},
author = {Timur M. Saliev and Prim B. Singh},
journal = {Central Asian Journal of Medical Hypotheses and Ethics},
year = {2025},
doi = {10.47316/cajmhe.2025.6.3.01},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International Journal of Veterinary Sciences and Animal Husbandry 2026
Open access · OA
Senotherapeutics: emerging pharmacological strategies for targeting cellular senescence
Biomolecules 2025
Open access · CC-BY
Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions
Med-X 2026
Open access · CC-BY
Modulating senescence for therapeutic delivery
Preprints.org 2025
Preprint · CC-BY
Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases
International Journal of Sciences and Innovation Engineering 2025
Open access · CC-BY
Pharmacology of Senolytics: Targeting Cellular Aging in Chronic Diseases
Signal Transduction and Targeted Therapy 2026
Open access · CC-BY